New Drug Approvals

Home » Posts tagged 'GSK-1614235 free base'

Tag Archives: GSK-1614235 free base

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,802,484 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

SUBSCRIBE

New Drug Approvals

↑ Grab this Headline Animator

Subscribe in a reader

Enter your email address:

Delivered by FeedBurner

Subscribe to New Drug Approvals by Email

Add to Google Reader or Homepage

Subscribe in Bloglines

Add to The Free Dictionary

I heart FeedBurner

Subscribe in NewsGator Online

Add to netvibes

Add to Excite MIX

Add to fwicki

Add to Webwag

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Mizagliflozin

September 10, 2025 2:57 am / Leave a comment


Mizagliflozin

  • CAS 666843-10-3
  • 1X96A704XV
  • DSP-3235
  • KGA-3235

WeightAverage: 564.68
Monoisotopic: 564.315914393

Chemical FormulaC28H44N4O8

  • Dsp-3235 free base
  • GSK-1614235 free base
  • Kga-3235 free base

2,2-dimethyl-3-[3-[3-methyl-4-[[5-propan-2-yl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]propylamino]propanamide

Mizagliflozin is an SGLT1 inhibitor developed as a potential treatment for chronic constipation.[1][2] It progressed as far as Phase II trials in humans but was not approved for medical use, however it has since been investigated for other applications.[3][4]

MIZAGLIFLOZIN is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.

Mizagliflozin is under investigation in clinical trial NCT05721729 (Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions).

an SGLT1 inhibitor; structure in first source

  • OriginatorKissei Pharmaceutical
  • DeveloperKissei Pharmaceutical; Vogenx
  • ClassAmides; Antihypoglycaemics; Laxatives; Pyrazoles; Small molecules
  • Mechanism of ActionSodium-glucose transporter 1 inhibitors
  • Phase IIHypoglycaemia
  • Phase IGastroparesis
  • PreclinicalUnspecified
  • DiscontinuedConstipation
  • 18 Jun 2025Phase-I clinical trials in Gastroparesis in USA (PO) (Vogenx pipeline, June 2025)
  • 18 Jun 2025Preclinical trials in Undisclosed rare disease in USA (PO) (Vogenx pipeline, June 2025)
  • 01 Oct 2019Chemical structure information added

LIT

str1

AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

……

Legal status
Legal statusInvestigational
Identifiers
IUPAC name
CAS Number666843-10-3
PubChem CID10460535
ChemSpider8635948
UNII1X96A704XV
ChEMBLChEMBL5314923
Chemical and physical data
FormulaC28H44N4O8
Molar mass564.680 g·mol−1
3D model (JSmol)Interactive image
SMILES
InChI

References

  1.  Inoue T, Takemura M, Fushimi N, Fujimori Y, Onozato T, Kurooka T, et al. (July 2017). “Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation”. European Journal of Pharmacology. 806: 25–31. doi:10.1016/j.ejphar.2017.04.010. PMID 28410751.
  2.  Fukudo S, Endo Y, Hongo M, Nakajima A, Abe T, Kobayashi H, et al. (September 2018). “Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial”. The Lancet. Gastroenterology & Hepatology. 3 (9): 603–613. doi:10.1016/S2468-1253(18)30165-1. PMID 30056028.
  3.  Ishida N, Saito M, Sato S, Tezuka Y, Sanbe A, Taira E, et al. (October 2021). “Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease”. Pharmacology Research & Perspectives. 9 (5): e00869. doi:10.1002/prp2.869. PMC 8480397. PMID 34586752.
  4.  Tsunokake S, Iwabuchi E, Miki Y, Kanai A, Onodera Y, Sasano H, et al. (October 2023). “SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast”. Breast Cancer Research and Treatment. 201 (3): 499–513. doi:10.1007/s10549-023-07024-9. PMID 37439959.

/////////666843-10-3, 1X96A704XV, DSP 3235, KGA 3235, Mizagliflozin, Dsp-3235 free base, GSK-1614235 free base, Kga-3235 free base